Most recent studies demonstrate that COVID-19 patients with higher numbers of CD4+ CD28null, CD8+ CD28null, or CD4+ CD28null and CD8+ CD28null populations (or presented as lower numbers of CD28+ populations in some studies) have higher morbidity and mortality rates [23,24,25]. This evidence concerns the gene CD8A and COVID-19.